Nu-Tek BioSciences, LLC, an innovative manufacturer of industrial ingredients used in the development and manufacturing of pharmaceuticals, announced today that the company will build a new manufacturing facility in Austin, Minnesota. This will be the first dedicated, animal-free peptone, and protein hydrolysate manufacturing facility in the U.S. This U.S. owned peptone manufacturing plant will help meet the rapidly growing demand for materials used to manufacture biologics.
For more than ten years, Nu-Tek BioSciences has been manufacturing and supplying peptones to the pharmaceutical industry and is uniquely qualified to provide large capacities of raw materials. The Company’s technology platform was developed to meet the growing demand for animal-free media components in the biopharma industry. This investment into manufacturing comes at a time when pharmaceutical companies are seeking solutions to mitigate supply chain risk. With the current pressures of COVID-19 vaccine manufacturing, this capacity will solidify the Company’s commitment to building businesses and assets with long-term sustainability.
Nu-Tek is currently supplying a critical component used in the manufacture of a COVID-19 vaccine.
“At Nu-Tek, we believe this expansion in the pharmaceutical industry brings the promise of a vibrant manufacturing industry to the Midwest,” said Thomas Yezzi, CEO, Nu-Tek BioSciences. “When we embarked on this project, with our core business as manufacturers, we required a very special location. Austin’s rich manufacturing background combined with the health technology and innovation from Minnesota’s Medical Alley cluster, the Hormel Institute and other leading healthcare institutions and universities, made Austin the perfect choice to build a world class manufacturing facility.”
Nu-Tek BioSciences, a solutions-based manufacturer, has successfully developed a portfolio of products for use in the pharmaceutical and industrial fermentation industries. Peptones and protein hydrolysates are commonly used in microbiological media, fermentation nutrient systems, as well as cell and tissue culture media. This Austin-based project has been conducted in consultation with local officials from the City of Austin, the Austin Port Authority, Austin Utilities, Mower County, Development Corporation of Austin (DCA) and the Community Venture Network. The new manufacturing facility will be built at Creekside Business Park with construction expected to begin in the Spring of 2021.